{"id":"https://openalex.org/W7148775475","doi":"https://doi.org/10.1158/1538-7445.am2026-4416","title":"Abstract 4416: Overcoming the limited monospecific target landscape in cancer via discovery of tumor selective AND and OR gate bispecifics","display_name":"Abstract 4416: Overcoming the limited monospecific target landscape in cancer via discovery of tumor selective AND and OR gate bispecifics","publication_year":2026,"publication_date":"2026-04-03","ids":{"openalex":"https://openalex.org/W7148775475","doi":"https://doi.org/10.1158/1538-7445.am2026-4416"},"language":"en","primary_location":{"id":"doi:10.1158/1538-7445.am2026-4416","doi":"https://doi.org/10.1158/1538-7445.am2026-4416","is_oa":false,"landing_page_url":"https://doi.org/10.1158/1538-7445.am2026-4416","pdf_url":null,"source":{"id":"https://openalex.org/S168522863","display_name":"Cancer Research","issn_l":"0008-5472","issn":["0008-5472","1538-7445"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","doyens","jufo-3","ki-jl-3","medline","norway-2"],"host_organization":"https://openalex.org/P4310320273","host_organization_name":"American Association for Cancer Research","host_organization_lineage":["https://openalex.org/P4310320273"],"host_organization_lineage_names":["American Association for Cancer Research"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Cancer Research","raw_type":"journal-article"},"volume":null,"type":"conference-abstract","indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5030971269","display_name":"Daniel A. Holdbrook","orcid":"https://orcid.org/0000-0002-8116-9208","observed_orcids":["https://orcid.org/0000-0002-8116-9208"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Daniel Holdbrook","raw_affiliation_strings":["Promatix Biosciences Ltd., London, United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Promatix Biosciences Ltd., London, United Kingdom","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5082220264","display_name":"Katherine A. Vousden","orcid":"https://orcid.org/0000-0002-0309-5960","observed_orcids":["https://orcid.org/0000-0002-0309-5960"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Katherine Vousden","raw_affiliation_strings":["Promatix Biosciences Ltd., London, United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Promatix Biosciences Ltd., London, United Kingdom","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5132919299","display_name":"Michael Hunter","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Michael Hunter","raw_affiliation_strings":["Promatix Biosciences Ltd., London, United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Promatix Biosciences Ltd., London, United Kingdom","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5078390502","display_name":"Roy Pettipher","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Roy Pettipher","raw_affiliation_strings":["Promatix Biosciences Ltd., London, United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Promatix Biosciences Ltd., London, United Kingdom","institution_ids":[]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5132858705","display_name":"Mark Edwards","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Mark Edwards","raw_affiliation_strings":["Promatix Biosciences Ltd., London, United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Promatix Biosciences Ltd., London, United Kingdom","institution_ids":[]}]}],"institutions":[],"countries_distinct_count":0,"institutions_distinct_count":0,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"86","issue":"7_Supplement","first_page":"4416","last_page":"4416"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11016","display_name":"Monoclonal and Polyclonal Antibodies Research","score":0.961899995803833,"subfield":{"id":"https://openalex.org/subfields/2741","display_name":"Radiology, Nuclear Medicine and Imaging"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T11016","display_name":"Monoclonal and Polyclonal Antibodies Research","score":0.961899995803833,"subfield":{"id":"https://openalex.org/subfields/2741","display_name":"Radiology, Nuclear Medicine and Imaging"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T12534","display_name":"Protein Degradation and Inhibitors","score":0.02019999921321869,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":0.0031999999191612005,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/bispecific-antibody-drug-conjugate","display_name":"bispecific antibody-drug conjugate","score":0.9980000257492065},{"id":"https://openalex.org/keywords/tumor-selectivity","display_name":"tumor selectivity","score":0.7120000123977661},{"id":"https://openalex.org/keywords/therapeutic-index","display_name":"therapeutic index","score":0.6349999904632568}],"concepts":[{"id":"https://openalex.org/C70721500","wikidata":"https://www.wikidata.org/wiki/Q177005","display_name":"Computational biology","level":1,"score":0.6449999809265137},{"id":"https://openalex.org/C41008148","wikidata":"https://www.wikidata.org/wiki/Q21198","display_name":"Computer science","level":0,"score":0.5213000178337097},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.45739999413490295},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.421999990940094},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.41839998960494995},{"id":"https://openalex.org/C2780980858","wikidata":"https://www.wikidata.org/wiki/Q110022","display_name":"Dual (grammatical number)","level":2,"score":0.41019999980926514},{"id":"https://openalex.org/C53105671","wikidata":"https://www.wikidata.org/wiki/Q14777816","display_name":"Rational design","level":2,"score":0.35359999537467957},{"id":"https://openalex.org/C14103023","wikidata":"https://www.wikidata.org/wiki/Q11681459","display_name":"Pairing","level":3,"score":0.34209999442100525},{"id":"https://openalex.org/C2776291640","wikidata":"https://www.wikidata.org/wiki/Q2912517","display_name":"Value (mathematics)","level":2,"score":0.3199000060558319},{"id":"https://openalex.org/C187191949","wikidata":"https://www.wikidata.org/wiki/Q1138496","display_name":"Profiling (computer programming)","level":2,"score":0.3160000145435333},{"id":"https://openalex.org/C2983331546","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer therapy","level":3,"score":0.3151000142097473},{"id":"https://openalex.org/C147483822","wikidata":"https://www.wikidata.org/wiki/Q103537","display_name":"Antigen","level":2,"score":0.3077999949455261},{"id":"https://openalex.org/C177264268","wikidata":"https://www.wikidata.org/wiki/Q1514741","display_name":"Set (abstract data type)","level":2,"score":0.3018999993801117},{"id":"https://openalex.org/C3020616263","wikidata":"https://www.wikidata.org/wiki/Q1216998","display_name":"Tumor cells","level":2,"score":0.2978000044822693},{"id":"https://openalex.org/C2779974597","wikidata":"https://www.wikidata.org/wiki/Q28448986","display_name":"Clinical Practice","level":2,"score":0.29030001163482666},{"id":"https://openalex.org/C1491633281","wikidata":"https://www.wikidata.org/wiki/Q7868","display_name":"Cell","level":2,"score":0.28949999809265137},{"id":"https://openalex.org/C90559484","wikidata":"https://www.wikidata.org/wiki/Q778379","display_name":"Expression (computer science)","level":2,"score":0.2856999933719635},{"id":"https://openalex.org/C18431079","wikidata":"https://www.wikidata.org/wiki/Q1502169","display_name":"Gene expression profiling","level":4,"score":0.28519999980926514},{"id":"https://openalex.org/C60644358","wikidata":"https://www.wikidata.org/wiki/Q128570","display_name":"Bioinformatics","level":1,"score":0.27619999647140503},{"id":"https://openalex.org/C96232424","wikidata":"https://www.wikidata.org/wiki/Q4118072","display_name":"Cancer cell","level":3,"score":0.25999999046325684},{"id":"https://openalex.org/C104317684","wikidata":"https://www.wikidata.org/wiki/Q7187","display_name":"Gene","level":2,"score":0.25690001249313354}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1158/1538-7445.am2026-4416","doi":"https://doi.org/10.1158/1538-7445.am2026-4416","is_oa":false,"landing_page_url":"https://doi.org/10.1158/1538-7445.am2026-4416","pdf_url":null,"source":{"id":"https://openalex.org/S168522863","display_name":"Cancer Research","issn_l":"0008-5472","issn":["0008-5472","1538-7445"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","doyens","jufo-3","ki-jl-3","medline","norway-2"],"host_organization":"https://openalex.org/P4310320273","host_organization_name":"American Association for Cancer Research","host_organization_lineage":["https://openalex.org/P4310320273"],"host_organization_lineage_names":["American Association for Cancer Research"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Cancer Research","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3","score":0.7246000170707703}],"sustainable_development_goals_aurora":[],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":[],"abstract_inverted_index":{"Abstract":[0],"The":[1],"pool":[2],"of":[3,60,113,152,162,168,235,243,278,308,319],"membrane":[4],"proteins":[5],"suitable":[6],"for":[7,44,323],"monospecific":[8,154,273,301],"antibody-drug":[9],"conjugates":[10],"(ADCs)":[11],"is":[12,156,270],"inherently":[13],"limited,":[14],"restricting":[15],"tumor":[16,102,189,309],"selectivity":[17,144,186],"and":[18,46,107,122,247,280,312],"leaving":[19],"many":[20],"cancers":[21],"without":[22],"actionable":[23],"antigens.":[24],"Bispecific":[25],"ADCs":[26],"unlock":[27],"a":[28,90,199,255],"much":[29],"larger":[30],"combinatorial":[31],"target":[32,266,302],"universe":[33,151],"by":[34,172,182],"pairing":[35,209],"antigens,":[36],"enabling":[37,275],"AND-gate":[38,204,225],"designs":[39,48,178],"that":[40,49,68,93,149,254],"enforce":[41],"dual":[42,245],"expression":[43,190],"engagement":[45,246],"OR-gate":[47],"extend":[50],"coverage":[51],"where":[52],"individual":[53],"markers":[54],"are":[55,69],"insufficient.":[56],"However,":[57],"rational":[58],"construction":[59],"such":[61,237],"bispecifics":[62,315],"depends":[63],"on":[64],"identifying":[65],"antigen":[66],"pairs":[67],"co-expressed":[70],"in":[71,81,230,304],"tumors":[72],"but":[73],"absent":[74],"-":[75,80],"or":[76,133,184],"expressed":[77],"only":[78,198],"individually":[79],"normal":[82,105],"tissues.":[83],"To":[84],"meet":[85],"this":[86],"need,":[87],"we":[88],"developed":[89],"discovery":[91,259,307],"framework":[92],"combines":[94],"quantitative":[95],"proteomic":[96],"profiling":[97],"across":[98,125],"more":[99,281],"than":[100],"14":[101],"types,":[103],"matched":[104],"tissues,":[106],"cell":[108],"lines":[109],"with":[110,142,206,227,272],"computational":[111],"modeling":[112],"cancer-normal":[114],"specificity.":[115],"This":[116],"approach":[117],"systematically":[118],"evaluates":[119],"both":[120],"AND-":[121],"OR-logic":[123,177],"potential":[124],"all":[126],"bispecific":[127,195,258],"ADC":[128,196],"pairings":[129,171],"currently":[130],"under":[131],"clinical":[132,194],"preclinical":[134],"investigation,":[135],"while":[136,187],"also":[137],"uncovering":[138],"previously":[139],"unexplored":[140],"combinations":[141],"favorable":[143],"profiles.":[145],"Our":[146],"analysis":[147],"confirms":[148],"the":[150,160,166,207,211,218,221,240,264,276,299,320],"high-selectivity":[153],"targets":[155],"extremely":[157],"small,":[158],"whereas":[159],"application":[161],"AND-logic":[163],"markedly":[164],"expands":[165],"number":[167],"viable":[169],"tumor-restricted":[170,214],"exploiting":[173],"cancer-specific":[174],"co-expression":[175,215],"signatures.":[176],"provide":[179],"complementary":[180],"value":[181],"maintaining":[183],"improving":[185],"accommodating":[188],"heterogeneity.":[191],"Among":[192],"existing":[193],"programs,":[197],"limited":[200,300],"subset":[201],"demonstrates":[202],"true":[203],"behavior,":[205],"EGFR/MET":[208],"showing":[210],"most":[212],"robust":[213],"profile.":[216],"Beyond":[217],"current":[219],"landscape,":[220],"platform":[222,260],"identifies":[223],"novel":[224],"opportunities":[226],"predicted":[228],"improvements":[229],"therapeutic":[231,265],"index.":[232],"Functional":[233],"evaluation":[234],"one":[236],"candidate":[238],"validated":[239],"model\u2019s":[241],"prediction":[242],"avidity-driven":[244],"tumor-selective":[248],"cytotoxicity.":[249],"Collectively,":[250],"these":[251],"findings":[252],"demonstrate":[253],"proteomics-driven":[256],"AND/OR":[257],"can":[261],"substantially":[262],"expand":[263],"space":[267],"beyond":[268],"what":[269],"achievable":[271],"ADCs,":[274],"development":[277],"safer":[279],"selective":[282,310],"next-generation":[283],"cancer":[284,305],"therapeutics.":[285],"Citation":[286],"Format:":[287],"Daniel":[288],"Holdbrook,":[289],"Katherine":[290],"Vousden,":[291],"Michael":[292],"Hunter,":[293],"Roy":[294],"Pettipher,":[295],"Mark":[296],"Edwards.":[297],"Overcoming":[298],"landscape":[303],"via":[306],"AND":[311],"OR":[313],"gate":[314],"[abstract].":[316],"In:":[317],"Proceedings":[318],"American":[321],"Association":[322],"Cancer":[324,342],"Research":[325],"Annual":[326],"Meeting":[327],"2026;":[328],"Part":[329],"1":[330],"(Regular":[331],"Abstracts);":[332],"2026":[333],"Apr":[334],"17-22;":[335],"San":[336],"Diego,":[337],"CA.":[338],"Philadelphia":[339],"(PA):":[340],"AACR;":[341],"Res":[343],"2026;86(7":[344],"Suppl):Abstract":[345],"nr":[346],"4416.":[347]},"counts_by_year":[],"updated_date":"2026-09-25T08:18:29.962427","created_date":"2026-04-04T00:00:00"}